Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-07 pm EST
47.64 USD   +3.70%
01/18Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Price Target
MT
01/10Transcript : Ultragenyx Pharmaceutical Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM
CI
01/09Ultragenyx reports preliminary 2022 revenue guidance for 2023 revenue and cash usage pipeline updates and 2023 milestones
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about ULTRAGENYX PHARMACEUTICAL INC.
01/18Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Pr..
MT
01/10Transcript : Ultragenyx Pharmaceutical Inc. Presents at 41st Annual J.P. Morg..
CI
01/09Ultragenyx reports preliminary 2022 revenue guidance for 2023 revenue and cash usage pi..
AQ
01/06Ultragenyx Pharmaceutical Reports Preliminary 2022 Revenue, Issues 2023 Guidance
MT
01/06Ultragenyx Pharmaceutical Inc. : Results of Operations and Financial Condition, Regulation..
AQ
01/06Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; ..
GL
01/06Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; ..
AQ
01/06Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023
CI
01/04Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
2022HC Wainwright Assumes Ultragenyx With Buy Rating, $82 Price Target
MT
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th An..
CI
2022Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
2022Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
2022Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies..
CI
2022Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar..
CI
2022Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
MT
2022Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2022Ultragenyx Announces Departure of Chief Financial Officer
GL
2022Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice Presid..
CI
2022Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Chief Financial Offic..
CI
2022Ultragenyx to Present at Upcoming Healthcare Conferences
GL
2022Ultragenyx to Present at Upcoming Healthcare Conferences
AQ
2022Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps ..
MT
2022Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Targ..
MT
2022Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additio..
MT
2022ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
2022Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2..
CI
2022Ultragenyx : Q3 Earnings Snapshot
AQ
2022Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M
MT
2022Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
GL
2022Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
AQ
2022Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
2022Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022
CI
2022Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form..
AQ
2022Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corpora..
GL
2022Insider Sell: Ultragenyx Pharmaceutical
MT
2022Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $51 From $68, Maintains Neutr..
MT
2022Guggenheim Upgrades Ultragenyx Pharmaceutical to Buy From Neutral; Price Target is $50
MT
2022Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2022Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
2022Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
2022Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
2022Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual Bi..
CI
2022Ultragenyx to Participate at Citi BioPharma Conference
GL
2022Ultragenyx to Participate at Citi BioPharma Conference
AQ
2022Goldman Sachs Adjusts Price Target on Ultragenyx Pharmaceutical to $74 From $72, Reiter..
MT
2022Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2022Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
2022Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2022Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $142 From $146, Reiterat..
MT
2022Evercore ISI Downgrades Ultragenyx Pharmaceutical to In-Line From Outperform, Adjusts P..
MT
2022Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $68 From $70, Maintains Ne..
MT
2022Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
2022Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $130 From $135, Keep..
MT
2022ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
2022Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2..
CI
2022Ultragenyx Pharmaceutical : Reports Second Quarter 2022 Financial Results and Corporate Up..
PU
2022Ultragenyx Pharmaceutical Posts Wider Q2 Loss, Higher Revenue
MT
2022Ultragenyx : Q2 Earnings Snapshot
AQ
2022Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
2022Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q2 Revenue $89.3M
MT
2022Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
2022Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for Full Year 2022
CI
2022Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
2022Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
GL
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ULTRAGENYX PHARMACEUTICAL INC.